Marsh Martha H.
Known title: DirectorCIK: 0001500281
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
EW: FDA Flags High-Risk Device Recall After Patient Death. The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.
Transaction History
| AMN | ▲ Buy | Option Exercise | 6,275 | $0 | 4/19/2024 | View on chart |
| AMN | ▲ Buy | Option Exercise | 1,681 | $0 | 4/19/2024 | View on chart |
| AMN | ▲ Buy | Option Exercise | 22,575 | $0 | 4/19/2024 | View on chart |
| EW | ▲ Buy | Grant | 2,803 | $0 | 5/12/2023 | View on chart |
| AMN | ▲ Buy | Option Exercise | 1,458 | $0 | 4/21/2023 | View on chart |
| EW | ▲ Buy | Grant | 2,300 | $0 | 5/4/2022 | View on chart |
| EW | ▲ Buy | Option Exercise | 28,722 | $746K | 4/28/2022 | View on chart |
| EW | ▼ Sell | Open Market | 28,722 | $3.1M | 4/28/2022 | View on chart |
| AMN | ▲ Buy | Option Exercise | 2,139 | $0 | 4/21/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
AMN Healthcare Maintains Outperform Rating, Target Raised to $43
Analyst BMO Capital kept an Outperform rating on AMN Healthcare and increased its price target to $43. The company announced a third‑quarter 2026 earnings conference call scheduled for November 5. The stock trades near its $33.96 support level and carries a trailing P/E of 13.4, while analysts’ average target is $36.14.
AMN Healthcare Maintains Outperform Rating, Target Raised to $43. Analyst BMO Capital kept an Outperform rating on AMN Healthcare and increased its price target to $43. The company announced a third‑quarter 2026 earnings conference call scheduled for November 5. The stock trades near its $33.96 support level and carries a trailing P/E of 13.4, while analysts’ average target is $36.14.